@article{7da53e2e50014dd1bf24e8cd55dff805,
title = "Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.",
keywords = "GROWTH-FACTOR RECEPTOR, QUALITY-OF-LIFE, CLINICALLY SELECTED PATIENTS, TYROSINE KINASE INHIBITORS, RANDOMIZED PHASE-3 TRIAL, OPEN-LABEL, GENE-MUTATIONS, CARBOPLATIN-PACLITAXEL, ACQUIRED-RESISTANCE, ACHILLES HEAL",
author = "Wolfgang Br{\"u}ckl and Amanda Tufman and Huber, {Rudolf Maria}",
note = "Br{\"u}ckl: 1a Department of Respiratory Medicine, Allergology and Sleep Medicine , Paracelsus Medical University, General Hospital Nuernberg , Nuremberg , Germany.",
year = "2017",
doi = "10.1080/14737140.2017.1266265",
language = "English",
volume = "17",
pages = "143--155",
journal = "EXPERT REVIEW OF ANTICANCER THERAPY",
issn = "1473-7140",
publisher = "Future Drugs Ltd.",
number = "2",
}